PMC:7696151 / 105142-105624 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"4028","span":{"begin":255,"end":258},"obj":"Gene"},{"id":"4037","span":{"begin":350,"end":353},"obj":"Gene"},{"id":"4046","span":{"begin":76,"end":84},"obj":"Species"},{"id":"4120","span":{"begin":86,"end":89},"obj":"Chemical"},{"id":"4121","span":{"begin":101,"end":112},"obj":"Chemical"},{"id":"4122","span":{"begin":124,"end":134},"obj":"Chemical"},{"id":"4168","span":{"begin":61,"end":75},"obj":"Disease"}],"attributes":[{"id":"A4028","pred":"tao:has_database_id","subj":"4028","obj":"Gene:920"},{"id":"A4037","pred":"tao:has_database_id","subj":"4037","obj":"Gene:925"},{"id":"A4046","pred":"tao:has_database_id","subj":"4046","obj":"Tax:9606"},{"id":"A4120","pred":"tao:has_database_id","subj":"4120","obj":"MESH:D006886"},{"id":"A4121","pred":"tao:has_database_id","subj":"4121","obj":"MESH:D006918"},{"id":"A4122","pred":"tao:has_database_id","subj":"4122","obj":"MESH:D016049"},{"id":"A4168","pred":"tao:has_database_id","subj":"4168","obj":"MESH:D015658"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Paton, et al. (2005) [20] open-label, noncomparative stud17 HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.144 weeks Mean viral load was reduced by 1.6 log10 copies/mL below baseline (p = 0.001)CD4+ cell counts were significantly increased by a mean of 3.3 ± 6.9%, p = 0.095 at 144th week.CD8 cells percentage was reduced by 11.5 ± 14% per 48th week (p = 0.005) and remained around 10% until the 144th week Not reported."}

{"project":"LitCovid-sentences","denotations":[{"id":"T717","span":{"begin":0,"end":482},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Paton, et al. (2005) [20] open-label, noncomparative stud17 HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.144 weeks Mean viral load was reduced by 1.6 log10 copies/mL below baseline (p = 0.001)CD4+ cell counts were significantly increased by a mean of 3.3 ± 6.9%, p = 0.095 at 144th week.CD8 cells percentage was reduced by 11.5 ± 14% per 48th week (p = 0.005) and remained around 10% until the 144th week Not reported."}